SH3RF2: A Potential Therapeutic Target for Cisplatin Resistance in Ovarian Cancer

SH3RF2, also known as SH3 Domain Containing Ring Finger 2, belongs to the E3 ubiquitin ligase family and plays a crucial role in various physiological processes. It's involved in cell proliferation, differentiation, and regulation of the cell cycle. Additionally, it's implicated in cell migration, invasion, and has a significant impact on tumor development and metastasis. SH3RF2 is a recently discovered tumor suppressor gene, which plays a vital regulatory role in tumor occurrence and development.

Mutations and abnormal expression of SH3RF2 are associated with various diseases. For instance, in common tumors like breast cancer, lung cancer, and gastric cancer, the expression level of SH3RF2 is significantly lower compared to normal tissues. In ovarian cancer, the expression level of SH3RF2 is closely related to the survival rate of patients. Low expression levels are associated with a lower survival rate, and mutations or deletions of SH3RF2 are closely linked to ovarian cancer occurrence and development.

A study discovered a higher mutation rate of the SH3RF2 gene in ovarian cancer, which is associated with tumor grade and prognosis, suggesting that SH3RF2 mutations may be a driving factor in ovarian cancer. However, there is currently no research on the association between SH3RF2 and cisplatin resistance in ovarian cancer.

Therefore, this study aims to investigate the association between SH3RF2 and cisplatin resistance, along with exploring its molecular mechanisms. The findings from this study will provide a theoretical basis for considering SH3RF2 as a potential therapeutic target.